Releases

News

Releases

29. October, 2024

Cessatech company presentation – 29 Oct

Watch the recorded company presentation from Nordnet, and a new update from Ventis Pharma....

Read more

Releases

26. August, 2024

Cessatech and Proveca announce world-wide excluding US commercial partnership for CT001

Cessatech and Proveca enter an exclusive agreement for the commercialization of CT001 world-wide excluding...

Read more

Releases

12. August, 2024

Cessatech extends Loan Facility Agreement to DKK 10 million…

Cessatech extends its undrawn Loan Facility Agreement to DKK 10 million to support the...

Read more

Releases

5. July, 2024

Anders Dyhr Dombernowsky-Toft appointed to the Board of Directors

Cessatech has today appointed Anders Dyhr Dombernowsky-Toft to the Board of Directors at the...

Read more

Releases

28. June, 2024

New data on paediatric pain relief at the PAGE conference in Rome favouring its lead candidate CT001

On 28 June – Cessatech A/S (“Cessatech” or “the Company”) announces that the presentation...

Read more

Releases

3. June, 2024

Cessatech announces superior simulated pain efficacy in children

Cessatech announces the final simulated efficacy data in children with CT001 from the abstract...

Read more

Releases

27. May, 2024

Cessatech reports first patient dosed in final Safety Study 0202 of lead product candidate CT001

Cessatech A/S announces that the Safety Study 0202 has now been initiated with dosing...

Read more

Releases

29. February, 2024

Annual Report 2023

Cessatech A/S publishes its annual report for the fiscal year 2023, which also includes...

Read more

Releases

9. January, 2024

Cessatech 2024 major milestones and focus

Now is the time – 2024 will be an extremely busy and hopefully exciting...

Read more

Releases

4. January, 2024

Q&A session – topline data from Study 0205

Link to release: (Link to Q&A session-image)

Read more

Releases

22. December, 2023

Positive topline data from study 0205 with its lead candidate CT001 for the treatment of pain in children supporting further advancement of CT001

The study a double-blinded, randomised, placebo-controlled in adults demonstrated that CT001 was superior to...

Read more

Want to see all releases?

To see all releases including those not listed here, go to our filings and reports.

Stay up to date!

Subscribe and get notified on Cessatech's latest news.
An acceptance email will be sent to you, please check your spam.